{"id":341,"date":"2016-07-13T07:59:31","date_gmt":"2016-07-13T07:59:31","guid":{"rendered":"http:\/\/www.farmacovigilanciacanarias.org\/noticias\/?p=341"},"modified":"2016-07-13T07:59:31","modified_gmt":"2016-07-13T07:59:31","slug":"nota-informativa-muh-fv-142016","status":"publish","type":"post","link":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/2016\/07\/13\/nota-informativa-muh-fv-142016\/","title":{"rendered":"Nota Informativa MUH (FV), 14\/2016"},"content":{"rendered":"<table class=\"tablaHome\">\n<tbody>\n<tr>\n<td><a href=\"http:\/\/www.aemps.gob.es\/informa\/notasInformativas\/medicamentosUsoHumano\/seguridad\/2016\/NI-MUH_FV_14-idelalisib.htm\">Idelalisib (\u25bcZydelig\u00ae): conclusiones de la revaluaci\u00f3n europea de su balance beneficio-riesgo. (Recomendaciones del Comit\u00e9 para la Evaluaci\u00f3n de Riesgos en Farmacovigilancia Europeo-PRAC). Informaci\u00f3n para profesionales sanitarios<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Idelalisib (\u25bcZydelig\u00ae): conclusiones de la revaluaci\u00f3n europea de su balance beneficio-riesgo. (Recomendaciones del Comit\u00e9 para la Evaluaci\u00f3n de Riesgos en Farmacovigilancia Europeo-PRAC). Informaci\u00f3n para profesionales sanitarios<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-341","post","type-post","status-publish","format-standard","hentry","category-seguridad"],"_links":{"self":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts\/341","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/comments?post=341"}],"version-history":[{"count":1,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts\/341\/revisions"}],"predecessor-version":[{"id":342,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts\/341\/revisions\/342"}],"wp:attachment":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/media?parent=341"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/categories?post=341"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/tags?post=341"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}